Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Articles

The approval of concizumab-mtci (Alhemo) injection marks a significant milestone in managing hemophilia A and B with inhibitors by preventing or reducing bleeding episodes in adults and children 12 years and older.

First Subcutaneous Prophylaxis for Hemophilia A and B With Inhibitors Approved by FDA

Cameron Santoro is an associate editor for 

), AJMC.com, and The Center for Biosimilars

Racial and ethnic disparities are found among Asian individuals as they experience the highest lifetime incidence of alopecia areata, and Black individuals face a disproportionately higher risk of anxiety disorders associated with the condition.

Alopecia Areata Linked to Mental Health, Socioeconomic, Racial Disparities

Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®.

She has a BA in English language and literature from Rutgers University. You can connect with Julia on 

Although intravitreal faricimab helped to decrease central subfield thickness (CST) in patients with eyes previously treated for neovascular age-related macular degeneration, best corrected visual acuity showed no sign of improvement.

Intravitreal Faricimab Associated With Increased Treatment Interval, Decreased CST

Rose is an associate editorial director at 

She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on 

The approval marks the second for a generic in this class of medications indicated to improve glycemic control in patients with type 2 diabetes as a complement to diet and exercise.

FDA Approves First Generic Daily GLP-1 Injection for Type 2 Diabetes

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiovascular

Chronic Kidney Disease

Diabetes

Heart Failure

Type 1 Diabetes

Cardiorenalmetabolic

Alopecia

Atopic Dermatitis

Psoriasis

Dermatology

Gastroenterology

ALL/AML

CLL/SLL

GVHD

Hemophilia

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Rare Blood

Hematology

Liver

Hepatology

Autoimmune

Inflammation

Lupus

Myasthenia Gravis

Immunology

COVID-19

Vaccines

Infectious Disease

Major Depressive Disorder

Sleep

Mental Health

Duchenne Muscular Dystrophy

Epilepsy

Multiple Sclerosis

Parkinson Disease

Neurology

Obesity

Breast Cancer

Cholangiocarcinoma

Colorectal Cancer

Immuno-Oncology

Liver Cancer

Lung Cancer

Non–Small Cell Lung Cancer

Ovarian Cancer

Prostate Cancer

Skin Cancer

Soft Tissue Sarcoma

Oncology

Ophthalmology

COPD

Pulmonary Arterial Hypertension

Pulmonology

Spinal Muscular Atrophy

Rare Disease

Asthma

Idiopathic Pulmonary Fibrosis

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Employers

Medicare

Reimbursement

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

Participating Faculty

Introduction: Current Concepts in Hypertension Management and A Look Toward the Future

The Sixth Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure

Gene Polymorphism Influences Response to Angiotensin Blockade

New Drug Class Offers Benefits in Heart Failure

Comparative Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blocking Agents on Left Ventricular Volumes in Elderly Patients with Heart Failure

Phase I Results of the Randomized Evaluation of Left Ventricular Dysfunction (RESOLVD) Trial

European Society of Cardiology: Angiotensin II Antagonists:  Why is There So Much Excitement?

What are the Pharmacological Differences Between Angiotensin II Antagonists

Clinical Implications of Differences Between Angiotensin II Antagonists

Exploring the Benefits Beyond Blood Pressure Control

How Far Have We Come in Treating Congestive Heart Failure?

Rationale for Angiotensin Receptor Blockers in Congestive Heart Failure

Angiotensin Receptor Blockers: Cardio-renal Implications in Patients with Congestive Heart Failure

Selected Abstracts

New and Emerging Therapies in the Treatment of Hypertension and Congestive Heart Failure

Supplements and Featured Publications

SUPPLEMENT CONTENT

Supplements

Publications